Research: $400m jab for key cancer treatment

A Melbourne research institute has scored a $400 million royalties windfall for its groundbreaking anti-cancer medicine. The Walter and Eliza Hall Institute of Medical Research has partially sold the royalty rights to venetoclax, a treatment that inhibits a protein that makes cancer cells in chronic lymphocytic leukaemia patients resistant to other therapies. The Australian Financial Review, 28 July 2017, page 8; The Australian, 28 July 2017, page 19; The Daily Telegraph, 28 July 2017, page 20

#Research #Treatment #Cancer #LymphocyticLeukaemia #MyeloidLeukaemia #Therapy